Details of the Drug Combinations

General Information of This Drug (ID: DMICA9H)

• Drug Name: Sulfasalazine (DMICA9H)
• Synonyms: sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine

Indication

Irritable bowel syndrome; ICD 11: DD91.0; Status: Approved [1]; Rheumatoid arthritis; ICD 11: FA20; Status: Approved [2]; Ulcerative colitis; ICD 11: DD71; Status: Approved [3]

• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

10 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ambrisentan + Sulfasalazine	DCZ0SD6	Ambrisentan	Pulmonary Arterial Hypertension	[4]
Fexofenadine + Sulfasalazine	DC1E5J4	Fexofenadine	Pharmacokinetics	[5]
Methotrexate + Sulfasalazine	DCL7YBJ	Methotrexate	Chronic Nonbacterial Osteomyelitis	[6]
Naloxone + Sulfasalazine	DC54IXR	Naloxone	Intestinal Obstruction	[7]
Rolapitant + Sulfasalazine	DCLJ519	Rolapitant	Chemotherapy-induced Nausea and Vomiting	[8]
Sulfasalazine + Loperamide	DC6ZN1P	Loperamide	Intestinal Obstruction	[7]
Celecoxib + Sulfasalazine	DCD8TNG	Celecoxib	Ankylosing Spondylitis	[9]
Methotrexate + Sulfasalazine	DC4YGOL	Methotrexate	Rheumatoid Arthritis	[10]
Methotrexate + Sulfasalazine	DC5KP7N	Methotrexate	Arthritis, Rheumatoid	[11]
Methotrexate + Sulfasalazine	DC9EHO7	Methotrexate	Psoriatic Arthritis	[12]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4840).
• [3] Sulfasalazine FDA Label
• [4] ClinicalTrials.gov (NCT04528056) Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
• [5] ClinicalTrials.gov (NCT03012763) Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums
• [6] ClinicalTrials.gov (NCT04725422) CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)
• [7] ClinicalTrials.gov (NCT01596764) Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
• [8] ClinicalTrials.gov (NCT02434861) An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
• [9] ClinicalTrials.gov (NCT02638896) Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
• [10] ClinicalTrials.gov (NCT03813771) Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-nave Early RA Patients Based on nave T-cell Stratification
• [11] ClinicalTrials.gov (NCT02374021) Treatments Against RA and Effect on FDG-PET/CT
• [12] ClinicalTrials.gov (NCT03739853) Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial